The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death.
about
The human cytomegalovirus UL11 protein interacts with the receptor tyrosine phosphatase CD45, resulting in functional paralysis of T cellsModulation of CD6 function through interaction with Galectin-1 and -3Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell deathGalectin-1 research in T cell immunity: past, present and futureGalectins and their ligands: negative regulators of anti-tumor immunityRegulation of the metastatic cell phenotype by sialylated glycansProtein glycosylation in cancers and its potential therapeutic applications in neuroblastomaST6Gal-I regulates macrophage apoptosis via α2-6 sialylation of the TNFR1 death receptorThe Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell PhenotypeO-glycan inhibitors generate aryl-glycans, induce apoptosis and lead to growth inhibition in colorectal cancer cell lines.Protein engineering of conger eel galectins by tracing of molecular evolution using probable ancestral mutants.N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death.Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling.Alpha2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling.Role for hepatic and circulatory ST6Gal-1 sialyltransferase in regulating myelopoiesis.Mutational tuning of galectin-3 specificity and biological function.T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.Advanced mass spectrometry and chemical analyses reveal the presence of terminal disialyl motif on mouse B-cell glycoproteins.Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function.β-Galactoside α2,6-sialyltranferase 1 promotes transforming growth factor-β-mediated epithelial-mesenchymal transition.T-cell growth, cell surface organization, and the galectin-glycoprotein lattice.Characterizing the glycome of the mammalian immune system.Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cellsNovel innate immune functions for galectin-1: galectin-1 inhibits cell fusion by Nipah virus envelope glycoproteins and augments dendritic cell secretion of proinflammatory cytokinesThe role of galectins in the initiation, amplification and resolution of the inflammatory response.Epithelial-to-Mesenchymal Transition of RPE Cells In Vitro Confers Increased β1,6-N-Glycosylation and Increased Susceptibility to Galectin-3 Binding.The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.Galectin-1 regulates tissue exit of specific dendritic cell populations.Regulatory roles of galectins in the immune response.Galectin-1 as a potential cancer target.Galectins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease.When galectins recognize glycans: from biochemistry to physiology and back againThe coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders.Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death.Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes.Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells.Receptor tyrosine phosphatase beta (RPTPbeta) activity and signaling are attenuated by glycosylation and subsequent cell surface galectin-1 binding.T cell apoptosis at the maternal-fetal interface in early human pregnancy, involvement of galectin-1.Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines
P2860
Q21090492-11EBEFA9-E394-4DA7-83E2-56FF325EA1B4Q24299519-20964A2B-3C0A-4982-A3D3-C40E2F9D1A14Q24685820-C3156B06-3E65-410E-81C7-9B5AB63B07DBQ26825120-4ED0C5A3-E1AD-4D24-8F17-371C8B03149FQ27024580-FDB36654-FBBC-4E33-AF73-8E9C58A0E7EDQ27027559-F2D986CC-5AC6-40F4-AA11-0A259314AB54Q28069952-5C7933D7-6FB5-46B0-98FB-D3C32ED98A23Q28579333-336029BA-58E4-4104-8FCC-A6A16BA5BAFEQ30276749-E4A3622A-22F6-4BEA-A6C9-8BA28D3099E7Q33397243-35683BDC-D9F9-4DAF-BB7A-9622DAD3CB00Q33530944-1431D0EA-7606-4970-ACC0-9171721277CEQ33593811-EE791C1F-2190-42E2-BFCB-FBAF06F34DCCQ33610889-C9EA6738-EDEB-4B8C-84FA-2738FEB5B05DQ33673746-0E7E52AE-8E7F-4CE3-A4CD-BFF360F1BCC0Q34042797-64456C5C-978A-4ECD-BDE1-7CDED35EA7A6Q34251455-C2FC832B-B21D-4294-8AD8-798290AEC023Q34307798-A48DA547-8299-4146-9D62-254BED929FA1Q34567707-FC7F4B9E-0EA0-4BC3-B618-EDBC285FD5BAQ34676070-3F0E5EA8-0E78-40BB-B9CC-F088F1DF4C5EQ34683204-A5350779-D766-464B-ADBB-9B9513FB0632Q34691040-D50F680A-35AB-439F-B94C-9360978BDE9EQ34813256-D9A67849-0600-44BD-AC08-E9C34B03A30AQ35067731-D767371F-2191-4658-822B-4A0047F2B8C0Q35597188-57C065D1-1A80-4B55-9715-91E745C72802Q35801757-2F53A700-4158-4002-BAED-5F4334C5BB7BQ35892475-BC5733E8-57FC-4FBC-82B5-E227CCA71977Q35920312-76C7858C-797C-409E-83D7-819C58D2E320Q36049988-3B944AD9-031F-4308-838B-1F9FB1AB3E67Q36073653-26E48EE5-2A4F-44FD-9CEF-914B969392B7Q36078029-3FAA57ED-0D68-405E-B8E6-EB6A9A626834Q36135442-09F0BAA3-08D2-4D37-A9BC-1A832ABD842EQ36196146-343D458B-28D4-4E63-9CF9-1D5DDF10E1EBQ36292670-206BFCFD-0C27-4596-8E8C-C15DD4F9317AQ36440083-7609D006-C975-4953-AFB1-B87D357A17E0Q36732791-2FDCA605-5E43-4EDF-A7DF-479E1368DA7AQ36903097-4F574BA0-65A7-47AE-B85C-53A25F619F30Q36981050-8134BB18-60A8-485B-A2E6-0C2226C0152CQ36985070-51852469-304F-42FF-BE04-74B32E1356B5Q37032635-412A3CA9-4B90-4568-B8EF-DA4CAA614B56Q37137360-AB7118A8-C174-4F15-933D-09F67C8F6A28
P2860
The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
The ST6Gal I sialyltransferase ...... modulation, and T cell death.
@en
type
label
The ST6Gal I sialyltransferase ...... modulation, and T cell death.
@en
prefLabel
The ST6Gal I sialyltransferase ...... modulation, and T cell death.
@en
P2093
P2860
P356
P1476
The ST6Gal I sialyltransferase ...... modulation, and T cell death.
@en
P2093
Linda G Baum
Maho Amano
Marisa Galvan
P2860
P304
P356
10.1074/JBC.M209595200
P407
P577
2002-12-23T00:00:00Z